182 results about "Pain chronic" patented technology

The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

The invention discloses stem cells for specifically expressing a programmed death receptor 1 (PD-1), and particularly relates to the stem cells from an organic cavity. The stem cells comprise but notlimited to dental pulp stem cells, gingival mesenchymal steam cells (GMSCs), periodontal ligament stem cells (PDLSCs), stem cells of apical papilla (SCAPs) and dental follicle stem cells (DFSCs) or any combination thereof, and preferably comprise stem cells from human exfoliated deciduous teeth (SHED) and/or dental pulp mesenchymal stem cells for permanent teeth (DPSC); the stem cells also includemesenchymal stem cells from other tissues, which do not express the PD-1 at first and express the PD-1 after being modified by CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), suchas PD-1 plus bone mesenchymal stem cells (BMMSC) modified by the CRISPR. The invention further discloses an identifying and separating method for the stem cells for specifically expressing the PD-1,a method for preparing the PD-1 plus mesenchymal stem cells modified by the CRISPR as well as application of the mesenchymal stem cells for expressing the PD-1, disclosed by the invention, in tissue regeneration, pain relief and treatment of chronic pain and a series of diseases.

The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.

The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

The present invention is directed to a compound of Formula I

or a pharmaceutically acceptable salt thereof; wherein R, R¹, R², R³, R⁴, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.

The invention discloses cathepsin S as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on cathepsin S enzyme activity and/or cathepsin S gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat chronic pain, comprising identifying compounds that can inhibit cathepsin S activity and/or gene expression which can also reverse the pathological effects of chronic pain in vivo.

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

A Chinese medicine in the form of oral liquid for treating the chronic pain caused by the peripheroneural damage is prepared from 5 Chinese medicinal materials including asarum herb, notoginseng, American ginseng, tremella, and pilose asiabell root on achyranthes bidentate through extracting polyose substances separately. The extracted polyose components have the function of repairing the nerve ending causing the chronic pain and contain no inhibitor on the nervous centralis. Its advantages are high curative effect, quickly taking its effect and no toxic by-effect.

The invention relates to deuterated pentazocine shown as formula I in the specification and pharmaceutically acceptable salts thereof. The invention also provides a novel compound serving as an analgesic for various acute and chronic pains, a preparation method, and a pharmaceutical composition containing the compound. Compared with undeuterated pentazocine, pharmacokinetics is improved, better metabolic stability is achieved, the half-life period of pentazocine is prolonged, and the bioavailability of pentazocine is improved.

The invention discloses a nucleic acid drug for treating chronic pain, and belongs to the field of analgesic drugs. The active component of the nucleic acid medicine is siRNA or shRNA for inhibiting NALCN expression, and in combination with specific lipidosome, cationic polymer micelle or adeno-associated virus vector, neuropathic pain and inflammatory pain can be effectively treated, and the lasting time of the medicine effect is long. The medicine provided by the invention is expected to replace the existing analgesic medicine and has a good application prospect.